Progyny, Inc. (PGNY) - Stock Analysis
Last updated: May 9, 2026
Research Idea
Research content for general circulation. Not individualized advice. Methodology & Disclosures
Healthcare services momentum with supportive fundamentals: record Q1 revenue of $328.5M, EPS beat, robust demand commentary, Progyny Select launch, and 8.8M shares repurchased since November. The stock surged about 45% over 21 trading days and 28% over the last five sessions, showing strong near-term follow-through.
Loading chart data...
AI Analyst Overview
Loading chart data...
Valuation Metrics
Fundamental Analysis
Key Financial Insights: ⢠Strong liquidity ⢠Rising margins ⢠Dilution pressure PGNY shows a strong balance sheet and cash generation with improving margins and solid returns, but heavy stock-based compensation, sizable receivables, and a rich valuation limit the upside.
Price Behavior
Key Price Behavior Insights: ⢠Higher lows ⢠Breakout hold ⢠Pullback risk Support Level: $18.40-$18.60 Resistance Level: $19.00-$19.20 Over the last month, PGNY has broken decisively above the $19 area with a series of higher lows and a higher base, signaling strong momentum but also an overextended move that could pause or pull back if follow-through fades.
Sentiment & News
Key News Insights: ⢠Product expansion ⢠Analyst upgrades ⢠Record Q1 beat PGNY's new fertility plan launch, favorable analyst ratings, and Q1 beat with record revenue signal improving momentum and strong demand in women's health.
AI Summary
PGNY now looks more like a cash-generating healthcare platform than a pure growth story, with improving margins, strong free cash flow, and buybacks supporting the case, but the stock still depends on proving it can sustain engagement, offset client churn, and prevent SBC dilution from eroding per-share gains.
Description
Progyny is a U.S. benefits management company that provides employer-sponsored fertility and family-building programs through tailored plan design, concierge-style member support, and a curated network of reproductive specialists. The company also offers an integrated pharmacy service for treatment medications and administers employer-funded surrogacy and adoption reimbursement programs. Incorporated in 2008 as Auxogyn and renamed Progyny in 2015, it is headquartered in New York City.
Idea History
| Date | Close | Ticker | Company | Summary | Status | P/L |
|---|---|---|---|---|---|---|
| May 11 | May 18 | PGNY | Progyny, Inc. | Healthcare services momentum with supportive fundamentals: record Q1 revenue of $328.5M, EPS beat, robust demand commentary, Progyny Select launch, and 8.8M shares repurchased since November. The stock surged about 45% over 21 trading days and 28% over the last five sessions, showing strong near-term follow-through. | Active | +0.0% |